210 related articles for article (PubMed ID: 29766409)
21. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
Gülben K; Berberoğlu U; Kinaş V; Başkan E
Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
[TBL] [Abstract][Full Text] [Related]
23. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
24. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008.
Cossetti RJ; Tyldesley SK; Speers CH; Zheng Y; Gelmon KA
J Clin Oncol; 2015 Jan; 33(1):65-73. PubMed ID: 25422485
[TBL] [Abstract][Full Text] [Related]
25. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant systemic therapy for breast cancer: the Westmead experience.
Cocco AM; Messer D; Brown A; Sriram N; Gilchrist J; Al-Mansouri L; Kefford R; Meybodi F; French J; Hsu J; Elder E
ANZ J Surg; 2018 Jun; 88(6):640-644. PubMed ID: 28922685
[TBL] [Abstract][Full Text] [Related]
27. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
28. Preoperative radiotherapy in breast cancer patients: 32 years of follow-up.
Riet FG; Fayard F; Arriagada R; Santos MA; Bourgier C; Ferchiou M; Heymann S; Delaloge S; Mazouni C; Dunant A; Rivera S
Eur J Cancer; 2017 May; 76():45-51. PubMed ID: 28267657
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
[TBL] [Abstract][Full Text] [Related]
30. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer.
Spanheimer PM; Carr JC; Thomas A; Sugg SL; Scott-Conner CE; Liao J; Weigel RJ
Am J Surg; 2013 Jul; 206(1):2-7. PubMed ID: 23375759
[TBL] [Abstract][Full Text] [Related]
31. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
34. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
[TBL] [Abstract][Full Text] [Related]
35. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
[TBL] [Abstract][Full Text] [Related]
36. Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.
Zhong Y; Xu Y; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Pan B; Wang C; Peng L; Huang X; Li Y; Wang X; Sun Q
Breast Cancer Res Treat; 2020 Jul; 182(1):117-126. PubMed ID: 32430680
[TBL] [Abstract][Full Text] [Related]
37. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
38. How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?
Barrio AV; Mamtani A; Edelweiss M; Eaton A; Stempel M; Murray MP; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3475-3480. PubMed ID: 27469123
[TBL] [Abstract][Full Text] [Related]
39. Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer--results for 804 Chinese patients from a single institution.
Xiao XS; Tang HL; Xie XH; Li LS; Kong YN; Wu MQ; Yang L; Gao J; Wei WD; Xie X
Asian Pac J Cancer Prev; 2013; 14(9):5219-23. PubMed ID: 24175804
[TBL] [Abstract][Full Text] [Related]
40. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]